Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients

Liver Transplantation

Volumn 8, Issue 2, 2002, Pages 123-131

  Calmus, Yvon ^{a,b,c,d,e,f,g,h,i,j}   Scheele, Johannes R ^{a,b,c,d,e,f,g,h,i,j}   Gonzalez Pinto, Ignacio ^{a,b,c,d,e,f,g,h,i,j}   Jaurrieta, Eduardo J ^{a,b,c,d,e,f,g,h,i,j}   Klar, Ernst ^{a,b,c,d,e,f,g,h,i,j}   Pageaux, Georges P ^{a,b,c,d,e,f,g,h,i,j}   Scudamore, Charles H ^{a,b,c,d,e,f,g,h,i,j}   Cuervas Mons, Valentin ^{a,b,c,d,e,f,g,h,i,j}   Metselaar, Herold J ^{a,b,c,d,e,f,g,h,i,j}   Prestele, Hans ^{a,b,c,d,e,f,g,h,i,j}   Girault, Daniele ^{a,b,c,d,e,f,g,h,i,j}  

^a Hopital Cochin ^*  (France)

^b HÔPITAL SAINT ELOI   (France)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^g Ciutat Sanitaria   (Spain)

^h British Columbia Transplant Society   (Canada)

ⁱ ERASMUS MEDICAL CENTER   (Netherlands)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CYCLOSPORIN A; CYTOKINE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE DISEASE; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTIVE SURGERY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HEPATITIS C VIRUS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOPROPHYLAXIS; INCIDENCE; INJECTION SITE; KIDNEY DISEASE; LIVER BIOPSY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; OLIGURIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; SKIN MANIFESTATION; TREMOR;

EID: 0036193103     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.30882     Document Type: Article

References (29)

1. Acute rejection episodes - Best predictor of long-term primary cadaveric renal transplant survival
2. An analysis of predictors of long-term cadaveric renal allograft survival
3. The impact of an acute rejection episode on long-term renal allograft survival (t 1/2)
4. Predictors of chronic rejection in renal transplant recipients
5. Early versus late acute renal allograft rejection: Impact on chronic rejection
6. Improved graft survival after renal transplantation in the United States, 1988 to 1996
7. Randomized trial of cyclosporine microemulsion (Neoral®) versus conventional cyclosporine in liver transplantation
8. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
9. The clinical and experimental use of monoclonal antibodies to the IL-2 receptor
10. Interleukin 2 receptor-targeted therapy-Rationale and applications in organ transplantation
11. Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions
12. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
13. Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts
14. Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation
15. Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients
16. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients
17. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
18. Pathology of liver allograft rejection
19. Enhanced risk of steroid-resistant acute rejection following pretransplant steroid therapy in liver graft recipients
20. Prophylactic use of OKT3 in liver transplantation: A review
21. Hepatitis C viral infection in liver transplantation
22. Recurrent hepatitis C viral hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation
23. Underlying disease as a predictor for rejection after liver transplantation
24. Comparison of histopathology in acute allograft rejection and recurrent hepatitis C infection after liver transplantation
25. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
26. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients
27. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients
28. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation